Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,386,260
  • Shares Outstanding, K 70,836
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -143,950 K
  • EBIT $ -194 M
  • EBITDA $ -185 M
  • 60-Month Beta 2.11
  • Price/Sales 21.23
  • Price/Cash Flow N/A
  • Price/Book 3.41

Options Overview Details

View History
  • Implied Volatility 90.79% ( +1.69%)
  • Historical Volatility 63.83%
  • IV Percentile 29%
  • IV Rank 56.69%
  • IV High 153.33% on 06/14/24
  • IV Low 8.94% on 03/19/24
  • Put/Call Vol Ratio 0.26
  • Today's Volume 140
  • Volume Avg (30-Day) 179
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 4,496
  • Open Int (30-Day) 3,755

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/24
See More
  • Average Estimate -0.67
  • Number of Estimates 8
  • High Estimate -0.51
  • Low Estimate -0.88
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +12.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.10 +2.46%
on 12/24/24
23.00 -14.91%
on 12/02/24
-2.48 (-11.25%)
since 11/22/24
3-Month
19.10 +2.46%
on 12/24/24
29.56 -33.80%
on 11/11/24
-4.71 (-19.40%)
since 09/24/24
52-Week
7.65 +155.82%
on 01/29/24
29.56 -33.80%
on 11/11/24
+10.00 (+104.49%)
since 12/22/23

Most Recent Stories

More News
Nurix Therapeutics Receives FDA Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia Treatment

Nurix Therapeutics announces FDA Fast Track designation for NX-5948, a drug targeting Waldenstrom’s macroglobulinemia.Quiver AI SummaryNurix Therapeutics, Inc. announced that the FDA has granted Fast...

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Reports Promising Phase 1a/1b Clinical Trial Results for NX-5948 in Relapsed or Refractory CLL/SLL at ASH Annual Meeting

Nurix Therapeutics reports promising NX-5948 trial results for CLL/SLL, highlighting response rates and safety profile. Webcast scheduled for updates.Quiver AI SummaryNurix Therapeutics, Inc. has reported...

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

NRIX : 19.57 (-2.05%)
Nurix Therapeutics to Host Webcast on Phase 1a/1b Trial Data for NX-5948 on December 9, 2024

Nurix Therapeutics to present NX-5948 clinical trial data in a webcast on December 9, 2024, featuring guest speaker Dr. Nirav N. Shah.Quiver AI SummaryNurix Therapeutics, Inc. announced a live webcast...

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

NRIX : 19.57 (-2.05%)
Nurix Therapeutics to Present Corporate Update at Piper Sandler Healthcare Conference on December 3, 2024

Nurix Therapeutics will present updates on its drug development at the Piper Sandler Healthcare Conference on December 3, 2024.Quiver AI SummaryNurix Therapeutics, Inc. announced that its president and...

NRIX : 19.57 (-2.05%)
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

NRIX : 19.57 (-2.05%)
Nurix Therapeutics Presents Preclinical Data on NX-5948 and GS-6791 at ACR Convergence 2024

Nurix Therapeutics presented preclinical data on NX-5948 and GS-6791 at ACR Convergence 2024, highlighting their potential in treating inflammatory diseases.Quiver AI SummaryNurix Therapeutics, Inc. has...

NRIX : 19.57 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 20.55
2nd Resistance Point 20.16
1st Resistance Point 19.87
Last Price 19.57
1st Support Level 19.19
2nd Support Level 18.80
3rd Support Level 18.51

See More

52-Week High 29.56
Fibonacci 61.8% 21.19
Last Price 19.57
Fibonacci 50% 18.60
Fibonacci 38.2% 16.02
52-Week Low 7.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar